New avenues in the medical treatment of Cushing’s disease: corticotroph tumor targeted therapy

[1]  L. Nieman,et al.  Cushing's syndrome , 2015, The Lancet.

[2]  N. Tritos,et al.  Medical management of Cushing’s disease , 2014, Journal of Neuro-Oncology.

[3]  P. Chanson,et al.  Management of hyperglycaemia in Cushing's disease: experts' proposals on the use of pasireotide. , 2012, Diabetes & metabolism.

[4]  J. Bertherat,et al.  Efficiency and tolerance of mitotane in Cushing's disease in 76 patients from a single center. , 2012, European journal of endocrinology.

[5]  M. Fleseriu.  Medical management of persistent and recurrent cushing disease. , 2012, Neurosurgery clinics of North America.

[6]  S. Schulz,et al.  Differential Expression of Somatostatin Receptor Subtype 1–5 Proteins in Numerous Human Normal Tissues , 2012, Experimental and Clinical Endocrinology & Diabetes (Barth).

[7]  E. Arvat,et al.  Potential role for retinoic acid in patients with Cushing's disease. , 2012, The Journal of clinical endocrinology and metabolism.

[8]  M. Fleseriu,et al.  Medical management of Cushing’s disease: what is the future? , 2012, Pituitary.

[9]  X. Bertagna,et al.  Patients with Cushing's disease achieve normal urinary cortisol with LCI699, a potent 11[beta]-hydroxylase inhibitor: preliminary results from a multicenter, proof-of-concept study , 2012 .

[10]  B. Scheithauer,et al.  Temozolomide in aggressive pituitary adenomas and carcinomas , 2012, Clinics.

[11]  M. Fleseriu,et al.  Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. , 2012, The Journal of clinical endocrinology and metabolism.

[12]  A. Colao,et al.  A 12-month phase 3 study of pasireotide in Cushing's disease. , 2012, The New England journal of medicine.

[13]  N. Tritos,et al.  Advances in medical therapies for Cushing's syndrome. , 2012, Discovery medicine.

[14]  M. Buchfelder,et al.  DG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumours. , 2012, European journal of endocrinology.

[15]  A. Mamelak,et al.  EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas. , 2011, The Journal of clinical investigation.

[16]  G. Stalla,et al.  Effect of SOM230 (Pasireotide) on Corticotropic Cells: Action in Dogs with Cushing’s Disease , 2011, Neuroendocrinology.

[17]  S. Mudaliar,et al.  Mechanism and management of hyperglycemia associated with pasireotide: results from studies in healthy volunteers , 2011 .

[18]  A. Magno,et al.  The calcium-sensing receptor: a molecular perspective. , 2011, Endocrine reviews.

[19]  S. Melmed,et al.  CHAPTER 8 – Pituitary Physiology and Diagnostic Evaluation , 2011 .

[20]  S. Petersenn.  Medical Management of Cushing’s Disease , 2011 .

[21]  S. Gultekin,et al.  Temozolomide for corticotroph pituitary adenomas refractory to standard therapy , 2011, Pituitary.

[22]  M. Reni,et al.  Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases. , 2010, European journal of endocrinology.

[23]  E. Laws,et al.  Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression. , 2010, The Journal of clinical endocrinology and metabolism.

[24]  A. Lacroix,et al.  Cabergoline monotherapy in the long-term treatment of Cushing's disease. , 2010, European journal of endocrinology.

[25]  J. Jørgensen,et al.  Epidemiology of Cushing’s Syndrome , 2010, Neuroendocrinology.

[26]  N. Shah,et al.  Efficacy of cabergoline in uncured (persistent or recurrent) Cushing disease after pituitary surgical treatment with or without radiotherapy. , 2010, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[27]  H. Hammes,et al.  SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases. , 2010, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[28]  Marco Boscaro,et al.  Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas , 2010, BMC endocrine disorders.

[29]  J. Romijn,et al.  Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease. , 2010, The New England journal of medicine.

[30]  P. Chanson,et al.  Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. , 2010, The Journal of clinical endocrinology and metabolism.

[31]  P. Chanson,et al.  Merits and pitfalls of mifepristone in Cushing's syndrome. , 2009, European journal of endocrinology.

[32]  P. Cappabianca,et al.  The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. , 2009, The Journal of clinical endocrinology and metabolism.

[33]  Y. Wang,et al.  Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. , 2009, The Journal of clinical endocrinology and metabolism.

[34]  S. Lamberts,et al.  Somatostatin and dopamine receptors as targets for medical treatment of Cushing’s Syndrome , 2009, Reviews in Endocrine and Metabolic Disorders.

[35]  Jeroen J. Bax,et al.  Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. , 2008, The Journal of clinical endocrinology and metabolism.

[36]  R. Murray,et al.  A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. , 2008, The Journal of clinical endocrinology and metabolism.

[37]  L. Nieman,et al.  Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. , 2008, The Journal of clinical endocrinology and metabolism.

[38]  L. Hofland.  Somatostatin and somatostatin receptors in Cushing's disease , 2008, Molecular and Cellular Endocrinology.

[39]  E. Laws,et al.  Late recurrences of Cushing's disease after initial successful transsphenoidal surgery. , 2008, The Journal of clinical endocrinology and metabolism.

[40]  V. G. Rasmussen,et al.  Heart valve disease associated with treatment with ergot‐derived dopamine agonists: a clinical and echocardiographic study of patients with Parkinson’s disease , 2007, Journal of internal medicine.

[41]  I. Morange,et al.  Ketoconazole revisited: a preoperative or postoperative treatment in Cushing's disease. , 2008, European journal of endocrinology.

[42]  R. McLendon,et al.  MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy , 2008, Acta Neuropathologica.

[43]  R. Strasser,et al.  Meta‐analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists , 2007, Movement disorders : official journal of the Movement Disorder Society.

[44]  A. Faggiano,et al.  Combined therapy of somatostatin analogues and dopamine agonists in the treatment of pituitary tumours. , 2007, European journal of endocrinology.

[45]  W. Haverkamp,et al.  Dopamine agonists and the risk of cardiac-valve regurgitation. , 2007, The New England journal of medicine.

[46]  I. Lancranjan,et al.  Dopamine D2 receptor gene expression in human adenohypophysial adenomas , 2001, Endocrine.

[47]  M. Givens,et al.  Antibacterial and Antifungal Agents , 2007 .

[48]  S. Lamberts,et al.  Preclinical and clinical experiences with the role of somatostatin receptors in the treatment of pituitary adenomas. , 2007, European journal of endocrinology.

[49]  C Susini,et al.  Rationale for the use of somatostatin analogs as antitumor agents. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[50]  C. Stratakis,et al.  The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. , 2006, The Journal of clinical endocrinology and metabolism.

[51]  F. Holsboer,et al.  Retinoic acid as a novel medical therapy for Cushing's disease in dogs. , 2006, Endocrinology.

[52]  L. Nieman,et al.  Cushing's syndrome , 2005 .

[53]  M. Buchfelder,et al.  Bone morphogenetic protein-4 inhibits corticotroph tumor cells: involvement in the retinoic acid inhibitory action. , 2006, Endocrinology.

[54]  M. Fernando,et al.  Alpha1-adrenergic receptor antagonists: novel therapy for pituitary adenomas. , 2005, Molecular endocrinology.

[55]  D. McCance,et al.  Long‐term remission rates after pituitary surgery for Cushing's disease: the need for long‐term surveillance , 2005, Clinical endocrinology.

[56]  P. Schoeffter,et al.  Regulation of CRH-induced secretion of ACTH and corticosterone by SOM230 in rats. , 2005, European journal of endocrinology.

[57]  D. Hoyer,et al.  Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells. , 2005, American journal of physiology. Endocrinology and metabolism.

[58]  S. Lamberts,et al.  The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. , 2005, European journal of endocrinology.

[59]  S. Raptis,et al.  Somatostatin: A potent inhibitor of ACTH-Hypersecretion in adrenal insufficiency , 1976, Klinische Wochenschrift.

[60]  Mark Hohenberg,et al.  The Epidemiological Approach , 2004 .

[61]  J. Kros,et al.  Dopamine receptor expression and function in corticotroph pituitary tumors. , 2004, The Journal of clinical endocrinology and metabolism.

[62]  S. Van Uum,et al.  Cortisol, 11beta-hydroxysteroid dehydrogenases, and hypertension. , 2004, Seminars in vascular medicine.

[63]  S. Lamberts,et al.  Somatostatin receptors in pituitary function, diagnosis and therapy. , 2004, Frontiers of hormone research.

[64]  Christian Bruns,et al.  Opportunities in somatostatin research: biological, chemical and therapeutic aspects , 2003, Nature Reviews Drug Discovery.

[65]  A. O'Carroll.  Localization of Messenger Ribonucleic Acids for Somatostatin Receptor Subtypes (sstr1–5) in the Rat Adrenal Gland , 2003, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[66]  G. Meno-Tetang,et al.  SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. , 2002, European journal of endocrinology.

[67]  E. Uhl,et al.  Retinoic acid prevents experimental Cushing syndrome. , 2001, The Journal of clinical investigation.

[68]  A. Hoffman,et al.  Novel long-acting somatostatin analog with endocrine selectivity: potent suppression of growth hormone but not of insulin. , 2001, Endocrinology.

[69]  Y. Patel.  Somatostatin and Its Receptor Family , 1999, Frontiers in Neuroendocrinology.

[70]  J D Veldhuis,et al.  Patients with Cushing's disease secrete adrenocorticotropin and cortisol jointly more asynchronously than healthy subjects. , 1998, The Journal of clinical endocrinology and metabolism.

[71]  J D Veldhuis,et al.  Greater disorderliness of ACTH and cortisol release accompanies pituitary-dependent Cushing's disease. , 1997, European journal of endocrinology.

[72]  S. Lamberts,et al.  Somatostatin analogue treatment of neuroendocrine tumours. , 1996, Postgraduate medical journal.

[73]  D. Engelhardt,et al.  Therapy of Cushing's syndrome with steroid biosynthesis inhibitors , 1994, The Journal of Steroid Biochemistry and Molecular Biology.

[74]  J. Etxabe,et al.  Morbidity and mortality in Cushing's disease: an epidemiological approach , 1994, Clinical endocrinology.

[75]  M. Buchfelder,et al.  Octreotide exerts different effects in vivo and in vitro in Cushing's disease. , 1994, European journal of endocrinology.

[76]  M. Berelowitz,et al.  Tissue distribution of somatostatin receptor subtype messenger ribonucleic acid in the rat. , 1993, Endocrinology.

[77]  C. Invitti,et al.  TREATMENT OF CUSHING'S SYNDROME WITH THE LONG‐ACTING SOMATOSTATIN ANALOGUE SMS 201‐995 (SANDOSTATIN) , 1990, Clinical endocrinology.

[78]  B. Ambrosi,et al.  Failure of somatostatin and octreotide to acutely affect the hypothalamic-pituitary-adrenal function in patients with corticotropin hypersecretion , 1990, Journal of endocrinological investigation.

[79]  J H Lewis,et al.  Drug-induced liver disease. , 2000, Clinics in liver disease.

[80]  S. Lamberts,et al.  The effect of the long-acting somatostatin analogue SMS 201-995 on ACTH secretion in Nelson's syndrome and Cushing's disease. , 1989, Acta endocrinologica.

[81]  J. Liu,et al.  Characterization of the twenty-four hour secretion patterns of adrenocorticotropin and cortisol in normal women and patients with Cushing's disease. , 1987, The Journal of clinical endocrinology and metabolism.

[82]  E. van Cauter,et al.  The 24-h cortisol secretory pattern in Cushing's syndrome. , 1986, Acta endocrinologica.

[83]  J. Kraicer,et al.  Release of pro-opiomelanocortin-derived peptides from the pars intermedia and pars distalis of the rat pituitary: effect of corticotrophin-releasing factor and somatostatin. , 1985, Neuroendocrinology.

[84]  R. Williams,et al.  Williams Textbook of endocrinology , 1985 .

[85]  W. Vale,et al.  Central nervous system regulation of adrenocorticotropin secretion: role of somatostatins. , 1984, Endocrinology.

[86]  R. Boyar,et al.  Circadian cortisol secretory rhythms in Cushing's disease. , 1979, The Journal of clinical endocrinology and metabolism.

[87]  H. Fehm,et al.  The effect of somatostatin and of prolyl-leucyl-glycinamide (MIF) on ACTH release in dispersed pituitary cells. , 1977, Life sciences.

[88]  M. Lorenzi,et al.  Inhibition by somatostatin of ACTH secretion in Nelson's syndrome. , 1975, The Journal of clinical endocrinology and metabolism.

[89]  D. Krieger,et al.  Relationship of bioassayable and immunoassayable plasma ACTH and cortisol concentrations in normal subjects and in patients with Cushing's disease. , 1975, The Journal of clinical endocrinology and metabolism.